Cervical Ca
54 programs · 54 companies
Programs
54
Companies
54
Trials
57
MOAs
35
CD47iPCSK9iPARPiJAK1iPI3KiPD-L1iKIF18AiKRASG12DiHPK1iSHP2i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Phase 2 | PRMT5 | ||
| AZN-4015 | Preclinical | BCMA | ||
| GSK-6516 | Phase 1/2 | MALT1 | ||
| Pexaosocimab | Phase 2 | PD-1 | ||
| REG-3155 | Phase 1/2 | MDM2 | ||
| Miriglumide | Phase 3 | CD3 | ||
| Fixaglumide | Phase 2/3 | WEE1 | ||
| Terarasimod | Phase 1/2 | PI3Kα | ||
| COR-9566 | Approved | TYK2 | ||
| Bemavorutinib | Phase 1/2 | WEE1 | ||
| DNL-9555 | Phase 1/2 | KIF18A | ||
| Surarelsin | Phase 3 | CGRP | ||
| Liraratamab | Phase 3 | SGLT2 | ||
| Voxazasiran | Phase 2/3 | JAK2 | ||
| Lisozanubrutinib | NDA/BLA | CD20 | ||
| Elratuximab | Phase 3 | BCMA | ||
| 452-670 | Approved | MALT1 | ||
| RDY-8710 | Approved | CD38 | ||
| MOR-3625 | NDA/BLA | GIP-R | ||
| TES-8949 | Phase 3 | AuroraA | ||
| Datocilimab | Approved | FLT3 | ||
| Teralemzoparlimab | Phase 2/3 | AuroraA | ||
| Tixafutibatinib | Phase 1/2 | USP1 | ||
| ONS-2940 | Phase 2 | Nectin-4 | ||
| VRN-4215 | Preclinical | PD-1 | ||
| Zanutapinarof | Approved | HER2 | ||
| KUM-1252 | Preclinical | Tau | ||
| Peminaritide | Phase 1/2 | Aβ | ||
| Gozemavacamten | Approved | CD20 | ||
| Capizanubrutinib | Preclinical | KRASG12C | ||
| 086-7390 | Phase 2/3 | GPRC5D | ||
| Elrabrutinib | Phase 3 | CD19 | ||
| Pemicilimab | Phase 2 | MET | ||
| Zanutuximab | Phase 1 | TIM-3 | ||
| NTR-8128 | Phase 3 | Nectin-4 | ||
| 051-2746 | Phase 2/3 | CFTR | ||
| 095-5475 | Preclinical | PSMA | ||
| Motanaritide | NDA/BLA | Aβ | ||
| Fixalucimab | Phase 2 | VEGF | ||
| NEO-1781 | NDA/BLA | DLL3 | ||
| Capirapivir | Approved | VEGF | ||
| Semazanubrutinib | Phase 3 | TROP-2 | ||
| Ivofutibatinib | Phase 3 | RET | ||
| Ceviglumide | Phase 1 | PLK4 | ||
| DIV-3233 | Phase 2/3 | PD-L1 | ||
| Gelinaritide | Phase 1/2 | FXIa | ||
| Elrabrutinib | Phase 2 | USP1 | ||
| RUI-IIT-543 | Phase 2/3 | B7-H3 | ||
| SEV-IIT-977 | Phase 3 | PD-1 | ||
| Rimatenlimab | Phase 2 | USP1 | ||
| Fixazanubrutinib | Preclinical | EZH2 | ||
| DEC-4099 | Phase 3 | VEGF | ||
| ZYM-7222 | Approved | PCSK9 | ||
| VEE-3535 | NDA/BLA | TIM-3 |
Trials (57)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT07724336 | Nirarelsin | Phase 2 | Recruiting |
| NCT06532619 | AZN-4015 | Preclinical | Completed |
| NCT03489631 | GSK-6516 | Phase 1/2 | Recruiting |
| NCT08267545 | Pexaosocimab | Phase 2 | Recruiting |
| NCT04980972 | REG-3155 | Phase 1/2 | Terminated |
| NCT07539730 | Fixaglumide | Phase 2/3 | Not yet recr... |
| NCT05217748 | Terarasimod | Phase 1/2 | Completed |
| NCT04934968 | Bemavorutinib | Phase 1/2 | Completed |
| NCT07858611 | DNL-9555 | Phase 1/2 | Completed |
| NCT08470377 | Surarelsin | Phase 3 | Recruiting |
| NCT04245290 | Surarelsin | Phase 3 | Not yet recr... |
| NCT08519547 | Liraratamab | Phase 3 | Not yet recr... |
| NCT07474659 | Lisozanubrutinib | NDA/BLA | Completed |
| NCT03958503 | Elratuximab | Phase 3 | Recruiting |
| NCT05373233 | 452-670 | Approved | Active |
| NCT04098640 | 452-670 | Approved | Not yet recr... |
| NCT07811505 | RDY-8710 | Approved | Completed |
| NCT08247375 | RDY-8710 | Approved | Completed |
| NCT08413023 | RDY-8710 | Approved | Completed |
| NCT04771638 | MOR-3625 | NDA/BLA | Not yet recr... |